Cell Projects (UK) has entered into a wide-ranging commercial licence and joint development agreement with Queen's University, Ontario, Canada.
It covers several electroporation platform technologies for Adherent and Insitu cell electroporation.
The technology allows DNA, peptides, SiRNA and many other molecules to be gently transported into cultured, adherent cells while the cells are still attached to their growing surface.
The data shows dramatic improvements of sensitivity and operation over existing methodologies.
Tom Hole, managing director at Cell Projects said: 'The Insitu technology will enable a greater understanding of specific cellular activities that to date have been difficult to analyse yet are known to be important in further understanding the mechanism of cancer, and other biological problems.'
